CANF - Can-Fite BioPharma Ltd.

NYSE American - Nasdaq Real Time Price. Currency in USD

Can-Fite BioPharma Ltd.

10 Bareket Street
Kiryat Matalon
Petah-Tikva 4951778
972 3 924 1114

Full Time Employees7

Key Executives

Prof. Pnina Fishman Ph.D.Scientific Founder, Chief Exec. Officer & Director434.15kN/A69
Mr. Motti FarbsteinChief Operating & Financial Officer324.33kN/A53
Dr. Ilan Cohn Ph.D.Co-Founder & ChairmanN/AN/A63
Dr. Michael H. Silverman M.D., F.A.C.P.,FACRMedical DirectorN/AN/AN/A
Dr. Vibeke Strand M.D., FACP, FACR (USA)Sr. Clinical AdvisorN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Corporate Governance

Can-Fite BioPharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.